{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:00:31Z","timestamp":1770973231991,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.pan.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:51:42Z","timestamp":1752681102000},"page":"605-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonists (GLP-1RA) and acute pancreatitis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-1410","authenticated-orcid":false,"given":"David C.","family":"Whitcomb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.pan.2025.07.005_bib1","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pan.2025.07.005_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1364110","article-title":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.pan.2025.07.005_bib3","article-title":"Liraglutide-induced pancreatitis: a case report and literature review","volume":"15","author":"Javed","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.pan.2025.07.005_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pan.2025.06.018","article-title":"Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management","author":"Postlethwaite","year":"2025","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2025.07.005_bib5","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.pan.2025.07.005_bib6","article-title":"Worldwide variations in demographics, management, and outcomes of acute pancreatitis","author":"Matta","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.pan.2025.07.005_bib7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MPA.0000000000000229","article-title":"LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER trial","volume":"43","author":"Steinberg","year":"2014","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.pan.2025.07.005_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4291\/wjgp.v5.i4.405","article-title":"Contemporary review of drug-induced pancreatitis: a different perspective","volume":"5","author":"Hung","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"7","key":"10.1016\/j.pan.2025.07.005_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.pan.2025.07.005_bib10","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.pan.2025.07.005_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103116","article-title":"Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: a propensity matched global federated TriNetX database-based retrospective cohort study","volume":"18","author":"Nassar","year":"2024","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"10.1016\/j.pan.2025.07.005_bib12","doi-asserted-by":"crossref","first-page":"E1076","DOI":"10.1152\/ajpendo.00479.2010","article-title":"Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents","volume":"299","author":"Tatarkiewicz","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pan.2025.07.005_bib13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/db14-0883","article-title":"Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis","volume":"64","author":"Koehler","year":"2015","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.pan.2025.07.005_bib14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T21:06:39Z","timestamp":1755810399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390325001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1424390325001498"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2025.07.005","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists (GLP-1RA) and acute pancreatitis","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}